tiprankstipranks
Solid Biosciences (SLDB)
NASDAQ:SLDB
US Market

Solid Biosciences (SLDB) Stock Price & Analysis

431 Followers

SLDB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.81 - $8.20
Previous Close$5.76
Volume1.11M
Average Volume (3M)469.29K
Market Cap
$69.01M
Enterprise Value-$48.84M
Total Cash (Recent Filing)$142.88M
Total Debt (Recent Filing)$25.04M
Price to Earnings (P/E)-1.2
Beta1.77
Mar 13, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.61
Shares Outstanding20,177,440
10 Day Avg. Volume1,241,542
30 Day Avg. Volume469,285
Standard Deviation0.30
R-Squared0.07
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.48
Price to Sales (P/S)14.36
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-94.47
Enterprise Value/Gross Profit-6.03
Enterprise Value/Ebitda0.44
Forecast
Price Target Upside44.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4

Financials

Annual

Ownership Overview

2.03% Mutual Funds
78.05% Other Institutional Investors
19.92% Public Companies and
Individual Investors

SLDB FAQ

What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $1.81 and its highest was $8.20 in the past 12 months.
    What is Solid Biosciences’s market cap?
    Currently, no data Available
    When is Solid Biosciences’s upcoming earnings report date?
    Solid Biosciences’s upcoming earnings report date is Mar 13, 2024 which is in 93 days.
      How were Solid Biosciences’s earnings last quarter?
      Solid Biosciences released its earnings results on Nov 08, 2023. The company reported -$1.05 earnings per share for the quarter, beating the consensus estimate of -$1.182 by $0.132.
        Is Solid Biosciences overvalued?
        According to Wall Street analysts Solid Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Solid Biosciences pay dividends?
          Solid Biosciences does not currently pay dividends.
          What is Solid Biosciences’s EPS estimate?
          Solid Biosciences’s EPS estimate is -$1.02.
            How many shares outstanding does Solid Biosciences have?
            Solid Biosciences has 20,177,440 shares outstanding.
              What happened to Solid Biosciences’s price movement after its last earnings report?
              Solid Biosciences reported an EPS of -$1.05 in its last earnings report, beating expectations of -$1.182. Following the earnings report the stock price went down -23.656%.
                Which hedge fund is a major shareholder of Solid Biosciences?
                Among the largest hedge funds holding Solid Biosciences’s share is Perceptive Advisors LLC. It holds Solid Biosciences’s shares valued at 9M.
                  ---

                  Company Description

                  Solid Biosciences

                  Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.
                  ---

                  Top 5 ETFs holding SLDB

                  Name
                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  $386.54K
                  8
                  Up to five ETFs with an Outperform Smart Score that hold SLDB. The ETFs are listed according to market value of SLDB within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Adverum Biotechnologies
                  Amicus
                  Editas Medicine
                  Amarin
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis